Cargando…
Analysis of lung cancer risk model (PLCO(M2012) and LLP(v2)) performance in a community-based lung cancer screening programme
INTRODUCTION: Low-dose CT (LDCT) screening of high-risk smokers reduces lung cancer (LC) specific mortality. Determining screening eligibility using individualised risk may improve screening effectiveness and reduce harm. Here, we compare the performance of two risk prediction models (PLCO(M2012) an...
Autores principales: | , , , , , , , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BMJ Publishing Group
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7402560/ https://www.ncbi.nlm.nih.gov/pubmed/32631933 http://dx.doi.org/10.1136/thoraxjnl-2020-214626 |
_version_ | 1783566782999560192 |
---|---|
author | Lebrett, Mikey B Balata, Haval Evison, Matthew Colligan, Denis Duerden, Rebecca Elton, Peter Greaves, Melanie Howells, John Irion, Klaus Karunaratne, Devinda Lyons, Judith Mellor, Stuart Myerscough, Amanda Newton, Tom Sharman, Anna Smith, Elaine Taylor, Ben Taylor, Sarah Walsham, Anna Whittaker, James Barber, Phil V Tonge, Janet Robbins, Hilary A Booton, Richard Crosbie, Philip A J |
author_facet | Lebrett, Mikey B Balata, Haval Evison, Matthew Colligan, Denis Duerden, Rebecca Elton, Peter Greaves, Melanie Howells, John Irion, Klaus Karunaratne, Devinda Lyons, Judith Mellor, Stuart Myerscough, Amanda Newton, Tom Sharman, Anna Smith, Elaine Taylor, Ben Taylor, Sarah Walsham, Anna Whittaker, James Barber, Phil V Tonge, Janet Robbins, Hilary A Booton, Richard Crosbie, Philip A J |
author_sort | Lebrett, Mikey B |
collection | PubMed |
description | INTRODUCTION: Low-dose CT (LDCT) screening of high-risk smokers reduces lung cancer (LC) specific mortality. Determining screening eligibility using individualised risk may improve screening effectiveness and reduce harm. Here, we compare the performance of two risk prediction models (PLCO(M2012) and Liverpool Lung Project model (LLP(v2))) and National Lung Screening Trial (NLST) eligibility criteria in a community-based screening programme. METHODS: Ever-smokers aged 55–74, from deprived areas of Manchester, were invited to a Lung Health Check (LHC). Individuals at higher risk (PLCO(M2012) score ≥1.51%) were offered annual LDCT screening over two rounds. LLP(v2) score was calculated but not used for screening selection; ≥2.5% and ≥5% thresholds were used for analysis. RESULTS: PLCO(M2012) ≥1.51% selected 56% (n=1429) of LHC attendees for screening. LLP(v2) ≥2.5% also selected 56% (n=1430) whereas NLST (47%, n=1188) and LLP(v2) ≥5% (33%, n=826) selected fewer. Over two screening rounds 62 individuals were diagnosed with LC; representing 87% (n=62/71) of 6-year incidence predicted by mean PLCO(M2012) score (5.0%). 26% (n=16/62) of individuals with LC were not eligible for screening using LLP(v2) ≥5%, 18% (n=11/62) with NLST criteria and 7% (n=5/62) with LLP(v2) ≥2.5%. NLST eligible Manchester attendees had 2.5 times the LC detection rate than NLST participants after two annual screens (≈4.3% (n=51/1188) vs 1.7% (n=438/26 309); p<0.0001). Adverse measures of health, including airflow obstruction, respiratory symptoms and cardiovascular disease, were positively correlated with LC risk. Coronary artery calcification was predictive of LC ((adj)OR 2.50, 95% CI 1.11 to 5.64; p=0.028). CONCLUSION: Prospective comparisons of risk prediction tools are required to optimise screening selection in different settings. The PLCO(M2012) model may underestimate risk in deprived UK populations; further research focused on model calibration is required. |
format | Online Article Text |
id | pubmed-7402560 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | BMJ Publishing Group |
record_format | MEDLINE/PubMed |
spelling | pubmed-74025602020-08-17 Analysis of lung cancer risk model (PLCO(M2012) and LLP(v2)) performance in a community-based lung cancer screening programme Lebrett, Mikey B Balata, Haval Evison, Matthew Colligan, Denis Duerden, Rebecca Elton, Peter Greaves, Melanie Howells, John Irion, Klaus Karunaratne, Devinda Lyons, Judith Mellor, Stuart Myerscough, Amanda Newton, Tom Sharman, Anna Smith, Elaine Taylor, Ben Taylor, Sarah Walsham, Anna Whittaker, James Barber, Phil V Tonge, Janet Robbins, Hilary A Booton, Richard Crosbie, Philip A J Thorax Lung Cancer INTRODUCTION: Low-dose CT (LDCT) screening of high-risk smokers reduces lung cancer (LC) specific mortality. Determining screening eligibility using individualised risk may improve screening effectiveness and reduce harm. Here, we compare the performance of two risk prediction models (PLCO(M2012) and Liverpool Lung Project model (LLP(v2))) and National Lung Screening Trial (NLST) eligibility criteria in a community-based screening programme. METHODS: Ever-smokers aged 55–74, from deprived areas of Manchester, were invited to a Lung Health Check (LHC). Individuals at higher risk (PLCO(M2012) score ≥1.51%) were offered annual LDCT screening over two rounds. LLP(v2) score was calculated but not used for screening selection; ≥2.5% and ≥5% thresholds were used for analysis. RESULTS: PLCO(M2012) ≥1.51% selected 56% (n=1429) of LHC attendees for screening. LLP(v2) ≥2.5% also selected 56% (n=1430) whereas NLST (47%, n=1188) and LLP(v2) ≥5% (33%, n=826) selected fewer. Over two screening rounds 62 individuals were diagnosed with LC; representing 87% (n=62/71) of 6-year incidence predicted by mean PLCO(M2012) score (5.0%). 26% (n=16/62) of individuals with LC were not eligible for screening using LLP(v2) ≥5%, 18% (n=11/62) with NLST criteria and 7% (n=5/62) with LLP(v2) ≥2.5%. NLST eligible Manchester attendees had 2.5 times the LC detection rate than NLST participants after two annual screens (≈4.3% (n=51/1188) vs 1.7% (n=438/26 309); p<0.0001). Adverse measures of health, including airflow obstruction, respiratory symptoms and cardiovascular disease, were positively correlated with LC risk. Coronary artery calcification was predictive of LC ((adj)OR 2.50, 95% CI 1.11 to 5.64; p=0.028). CONCLUSION: Prospective comparisons of risk prediction tools are required to optimise screening selection in different settings. The PLCO(M2012) model may underestimate risk in deprived UK populations; further research focused on model calibration is required. BMJ Publishing Group 2020-08 2020-07-05 /pmc/articles/PMC7402560/ /pubmed/32631933 http://dx.doi.org/10.1136/thoraxjnl-2020-214626 Text en © Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. http://creativecommons.org/licenses/by-nc/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/. |
spellingShingle | Lung Cancer Lebrett, Mikey B Balata, Haval Evison, Matthew Colligan, Denis Duerden, Rebecca Elton, Peter Greaves, Melanie Howells, John Irion, Klaus Karunaratne, Devinda Lyons, Judith Mellor, Stuart Myerscough, Amanda Newton, Tom Sharman, Anna Smith, Elaine Taylor, Ben Taylor, Sarah Walsham, Anna Whittaker, James Barber, Phil V Tonge, Janet Robbins, Hilary A Booton, Richard Crosbie, Philip A J Analysis of lung cancer risk model (PLCO(M2012) and LLP(v2)) performance in a community-based lung cancer screening programme |
title | Analysis of lung cancer risk model (PLCO(M2012) and LLP(v2)) performance in a community-based lung cancer screening programme |
title_full | Analysis of lung cancer risk model (PLCO(M2012) and LLP(v2)) performance in a community-based lung cancer screening programme |
title_fullStr | Analysis of lung cancer risk model (PLCO(M2012) and LLP(v2)) performance in a community-based lung cancer screening programme |
title_full_unstemmed | Analysis of lung cancer risk model (PLCO(M2012) and LLP(v2)) performance in a community-based lung cancer screening programme |
title_short | Analysis of lung cancer risk model (PLCO(M2012) and LLP(v2)) performance in a community-based lung cancer screening programme |
title_sort | analysis of lung cancer risk model (plco(m2012) and llp(v2)) performance in a community-based lung cancer screening programme |
topic | Lung Cancer |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7402560/ https://www.ncbi.nlm.nih.gov/pubmed/32631933 http://dx.doi.org/10.1136/thoraxjnl-2020-214626 |
work_keys_str_mv | AT lebrettmikeyb analysisoflungcancerriskmodelplcom2012andllpv2performanceinacommunitybasedlungcancerscreeningprogramme AT balatahaval analysisoflungcancerriskmodelplcom2012andllpv2performanceinacommunitybasedlungcancerscreeningprogramme AT evisonmatthew analysisoflungcancerriskmodelplcom2012andllpv2performanceinacommunitybasedlungcancerscreeningprogramme AT colligandenis analysisoflungcancerriskmodelplcom2012andllpv2performanceinacommunitybasedlungcancerscreeningprogramme AT duerdenrebecca analysisoflungcancerriskmodelplcom2012andllpv2performanceinacommunitybasedlungcancerscreeningprogramme AT eltonpeter analysisoflungcancerriskmodelplcom2012andllpv2performanceinacommunitybasedlungcancerscreeningprogramme AT greavesmelanie analysisoflungcancerriskmodelplcom2012andllpv2performanceinacommunitybasedlungcancerscreeningprogramme AT howellsjohn analysisoflungcancerriskmodelplcom2012andllpv2performanceinacommunitybasedlungcancerscreeningprogramme AT irionklaus analysisoflungcancerriskmodelplcom2012andllpv2performanceinacommunitybasedlungcancerscreeningprogramme AT karunaratnedevinda analysisoflungcancerriskmodelplcom2012andllpv2performanceinacommunitybasedlungcancerscreeningprogramme AT lyonsjudith analysisoflungcancerriskmodelplcom2012andllpv2performanceinacommunitybasedlungcancerscreeningprogramme AT mellorstuart analysisoflungcancerriskmodelplcom2012andllpv2performanceinacommunitybasedlungcancerscreeningprogramme AT myerscoughamanda analysisoflungcancerriskmodelplcom2012andllpv2performanceinacommunitybasedlungcancerscreeningprogramme AT newtontom analysisoflungcancerriskmodelplcom2012andllpv2performanceinacommunitybasedlungcancerscreeningprogramme AT sharmananna analysisoflungcancerriskmodelplcom2012andllpv2performanceinacommunitybasedlungcancerscreeningprogramme AT smithelaine analysisoflungcancerriskmodelplcom2012andllpv2performanceinacommunitybasedlungcancerscreeningprogramme AT taylorben analysisoflungcancerriskmodelplcom2012andllpv2performanceinacommunitybasedlungcancerscreeningprogramme AT taylorsarah analysisoflungcancerriskmodelplcom2012andllpv2performanceinacommunitybasedlungcancerscreeningprogramme AT walshamanna analysisoflungcancerriskmodelplcom2012andllpv2performanceinacommunitybasedlungcancerscreeningprogramme AT whittakerjames analysisoflungcancerriskmodelplcom2012andllpv2performanceinacommunitybasedlungcancerscreeningprogramme AT barberphilv analysisoflungcancerriskmodelplcom2012andllpv2performanceinacommunitybasedlungcancerscreeningprogramme AT tongejanet analysisoflungcancerriskmodelplcom2012andllpv2performanceinacommunitybasedlungcancerscreeningprogramme AT robbinshilarya analysisoflungcancerriskmodelplcom2012andllpv2performanceinacommunitybasedlungcancerscreeningprogramme AT bootonrichard analysisoflungcancerriskmodelplcom2012andllpv2performanceinacommunitybasedlungcancerscreeningprogramme AT crosbiephilipaj analysisoflungcancerriskmodelplcom2012andllpv2performanceinacommunitybasedlungcancerscreeningprogramme |